 The purpose of this study is to evaluate the percentage of spleen largest lymph organ in the body response and symptom response of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis MF who are relapsed after or refractory to Janus Kinase JAK inhibitor treatment. 